Importer of Controlled Substances; Notice of Application, 49018-49019 [E7-16863]
Download as PDF
<![CDATA[
49018
Federal Register / Vol. 72, No. 165 / Monday, August 27, 2007 / Notices
Radian Tool & Engineering, Troy, MI;
and Savant Technology Group, Inc.,
Ann Arbor, MI have been added as
parties to this venture. Also, Anautics,
Inc., Oklahoma City, OK; Campfire
Interactive, Inc., Ann Arbor, MI;
Cleveland Advanced Manufacturing
Program (CAMP), Cleveland, OH; CorMet Inc., Brighton, MI; Fraunhofer USA,
Plymouth, MI; Integrated Technologies,
Inc., Danville, VT; Leszynski Group Inc.,
Bellevue, WA; Midwest Thermal Spray,
Farmington Hills, MI; and Raytheon
Systems Company, McKinney, TX have
withdrawn as parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and NCMS
intends to file additional written
notification disclosing all changes in
membership.
On February 20, 1987, NCMS filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on March 17, 1987 (52 FR 8375).
The last notification was filed with
the Department of Justice on February
15, 2007. A notice was published in the
Federal Register pursuant to Section
6(b) of the Act on March 15, 2007 (72
FR 12198).
J. Robert Kramer II,
Director of Operations, Antitrust Division.
[FR Doc. 07–4165 Filed 8–24–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
rmajette on PROD1PC64 with NOTICES
By Notice dated April 17, 2007, and
published in the Federal Register on
April 30, 2007, (72 FR 21298), Amri
Rensselaer, Inc. (formerly: Organichem
Corporation), 33 Riverside Avenue,
Rensselaer, New York 12144, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oxymorphone (9652), a basic class of
controlled substance listed in schedule
II.
The company plans on manufacturing
the listed controlled substance in bulk
for sale to its customer.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Amri
Rensselaer, Inc. to manufacture the
listed basic class of controlled substance
15:56 Aug 24, 2007
Jkt 211001
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–16856 Filed 8–24–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 5, 2007,
Boehringer Ingelheim Chemicals Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule I and II:
Drug
Manufacturer of Controlled
Substances; Notice of Registration
VerDate Aug<31>2005
is consistent with the public interest at
this time. DEA has investigated Amri
Rensselaer, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Schedule
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Fentanyl (9801) ............................
I
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than October 26, 2007.
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administraton, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–16855 Filed 8–24–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on June 5,
2007, Boehringer Ingelheim Chemicals,
Inc., 2820 N. Normandy Drive,
Petersburg, Virginia 23805, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to bulk
manufacture amphetamine.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
E:\FR\FM\27AUN1.SGM
27AUN1
49019
Federal Register / Vol. 72, No. 165 / Monday, August 27, 2007 / Notices
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
September 26, 2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–16863 Filed 8–24–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Prior to issuing a registration under 21
U.S.C. 952(a) (2) (B), and in accordance
with 21 CFR 1301.34 (a), this is notice
that on July 20, 2007, Cerilliant
Corporation, 811 Paloma Drive, Suite A,
Round Rock, TX 78664, made
application by renewal to the Drug
Enforcement Administration (DEA) for
registration as an importer of the basic
classes of controlled substances listed in
schedule I and II:
rmajette on PROD1PC64 with NOTICES
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Fenethylline (1503) .......................
Gamma
hydroxybutyric
acid
(2010).
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
VerDate Aug<31>2005
15:56 Aug 24, 2007
I
I
I
I
I
I
I
I
I
I
I
I
Jkt 211001
Drug
Schedule
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Phencyclidine (7471) ....................
N-Benzylpiperazine (7493) ...........
Etorphine (except HCI)(9056) ......
Heroin (9200) ...............................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Pholcodine (9314) ........................
Dextromoramide (9613) ...............
Dipipanone (9622) ........................
Trimeperidine (9646) ....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Poppy Straw Concentrate (9670)
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
Any bulk manufacturers who are
presently, or are applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC.
20537; or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 JeffersonDavis Highway, Alexandria, Virginia
22301; and must be filed no later than
September 26, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–16862 Filed 8–24–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated June 7, 2007 and
published in the Federal Register on
June 20, 2007, (72 FR 34040), Chattem
Chemicals, Inc., 3801 St. Elmo Avenue,
Building 18, Chattanooga, Tennessee
37409, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Methamphetamine (1105) ............
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
Schedule
II
II
II
II
The company plans to import the
listed controlled substances to
E:\FR\FM\27AUN1.SGM
27AUN1
]]>Agencies
[Federal Register Volume 72, Number 165 (Monday, August 27, 2007)]
[Notices]
[Pages 49018-49019]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16863]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on June 5, 2007, Boehringer
Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia
23805, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Phenylacetone
(8501), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance to bulk
manufacture amphetamine.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC
[[Page 49019]]
20537, or any being sent via express mail should be sent to Drug
Enforcement Administration, Office of Diversion Control, Federal
Register Representative (ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be filed no later than September
26, 2007.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e) and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substances in schedule I or II are and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-16863 Filed 8-24-07; 8:45 am]
BILLING CODE 4410-09-P
